{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:35:29Z","timestamp":1775284529140,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860034"],"award-info":[{"award-number":["81860034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160038"],"award-info":[{"award-number":["82160038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160405"],"award-info":[{"award-number":["82160405"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260035"],"award-info":[{"award-number":["82260035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212ACB206016"],"award-info":[{"award-number":["20212ACB206016"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20224BAB216037"],"award-info":[{"award-number":["20224BAB216037"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.gendis.2023.03.016","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T02:09:58Z","timestamp":1681265398000},"page":"993-1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy"],"prefix":"10.1016","volume":"11","author":[{"given":"Fangyi","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangmin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gendis.2023.03.016_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","article-title":"Leukemia stem cells: the root of chronic myeloid leukemia","volume":"6","author":"Zhou","year":"2015","journal-title":"Protein Cell"},{"key":"10.1016\/j.gendis.2023.03.016_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-981-13-7342-8_9","article-title":"Leukemia stem cells in chronic myeloid leukemia","volume":"1143","author":"Shan","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.gendis.2023.03.016_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2023.03.016_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.gendis.2023.03.016_bib5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.gendis.2023.03.016_bib6","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.gendis.2023.03.016_bib7","doi-asserted-by":"crossref","first-page":"742802","DOI":"10.3389\/fgene.2021.742802","article-title":"A review on the therapeutic role of TKIs in case of CML in combination with epigenetic drugs","volume":"12","author":"Amir","year":"2021","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.gendis.2023.03.016_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/obr.12942","article-title":"Emerging role of m6 A RNA methylation in nutritional physiology and metabolism","volume":"21","author":"Wu","year":"2020","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.gendis.2023.03.016_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.tig.2019.10.011","article-title":"The biogenesis and precise control of RNA m6A methylation","volume":"36","author":"Huang","year":"2020","journal-title":"Trends Genet"},{"issue":"13","key":"10.1016\/j.gendis.2023.03.016_bib10","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1093\/nar\/gkab378","article-title":"A comprehensive review of m6A\/m6Am RNA methyltransferase structures","volume":"49","author":"Oerum","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.gendis.2023.03.016_bib11","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.apsb.2022.01.003","article-title":"Detailed resume of RNA m6A demethylases","volume":"12","author":"Shen","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.gendis.2023.03.016_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-020-00872-8","article-title":"m6A-binding proteins: the emerging crucial performers in epigenetics","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.gendis.2023.03.016_bib13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.molcel.2019.04.025","article-title":"Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers","volume":"74","author":"Shi","year":"2019","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.gendis.2023.03.016_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11684-018-0654-8","article-title":"RNA m6A modification and its function in diseases","volume":"12","author":"Tong","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.gendis.2023.03.016_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fcell.2019.00116","article-title":"Interplay between N 6-methyladenosine (m6A) and non-coding RNAs in cell development and cancer","volume":"7","author":"Fazi","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.gendis.2023.03.016_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fonc.2019.00251","article-title":"N6-methyladenosine (m6A): a promising new molecular target in acute myeloid leukemia","volume":"9","author":"Ianniello","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.gendis.2023.03.016_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-017-0419-x","article-title":"Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia","volume":"10","author":"Kwok","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2023.03.016_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.stem.2017.11.016","article-title":"METTL14 inhibits hematopoietic stem\/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification","volume":"22","author":"Weng","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"7860","key":"10.1016\/j.gendis.2023.03.016_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.gendis.2023.03.016_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccell.2019.03.006","article-title":"Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia","volume":"35","author":"Huang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gendis.2023.03.016_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41421-018-0019-0","article-title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation","volume":"4","author":"Yue","year":"2018","journal-title":"Cell Discov"},{"issue":"33","key":"10.1016\/j.gendis.2023.03.016_bib22","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1038\/s41388-019-0861-z","article-title":"KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner","volume":"38","author":"Qian","year":"2019","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.gendis.2023.03.016_bib23","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1002\/jcp.29645","article-title":"KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer","volume":"235","author":"Miao","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.gendis.2023.03.016_bib24","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.2147\/OTT.S180954","article-title":"KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA","volume":"12","author":"Cheng","year":"2019","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.gendis.2023.03.016_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.canlet.2021.08.027","article-title":"VIRMA contributes to non-small cell lung cancer progression via N6-methyladenosine-dependent DAPK3 post-transcriptional modification","volume":"522","author":"Xu","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2023.03.016_bib26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.omtn.2019.11.022","article-title":"Epigenetic regulation of m6A modifications in human cancer","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"10.1016\/j.gendis.2023.03.016_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","article-title":"m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer","volume":"37","author":"Huang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gendis.2023.03.016_bib28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12935-021-01868-1","article-title":"Role of m6A methyltransferase component VIRMA in multiple human cancers (Review)","volume":"21","author":"Zhu","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.gendis.2023.03.016_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.celrep.2014.05.048","article-title":"Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites","volume":"8","author":"Schwartz","year":"2014","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.gendis.2023.03.016_bib30","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/carcin\/bgaa029","article-title":"Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux","volume":"41","author":"Li","year":"2020","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.gendis.2023.03.016_bib31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/jbmr.268","article-title":"Rab27a and Rab27b are involved in stimulation-dependent RANKL release from secretory lysosomes in osteoblastic cells","volume":"26","author":"Kariya","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.gendis.2023.03.016_bib32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/tra.12083","article-title":"Rab27 effectors, pleiotropic regulators in secretory pathways","volume":"14","author":"Fukuda","year":"2013","journal-title":"Traffic"},{"issue":"Pt 10","key":"10.1016\/j.gendis.2023.03.016_bib33","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1242\/jcs.01048","article-title":"The small GTPase Rab27B regulates amylase release from rat parotid acinar cells","volume":"117","author":"Imai","year":"2004","journal-title":"J Cell Sci"},{"issue":"5","key":"10.1016\/j.gendis.2023.03.016_bib34","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41375-018-0015-2","article-title":"miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding","volume":"32","author":"Peng","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.gendis.2023.03.016_bib35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3892\/ol.2016.4801","article-title":"Overexpression of Rab27B is correlated with distant metastasis and poor prognosis in ovarian cancer","volume":"12","author":"Ren","year":"2016","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.gendis.2023.03.016_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031789","article-title":"Direct imaging of RAB27B-enriched secretory vesicle biogenesis in lacrimal acinar cells reveals origins on a nascent vesicle budding site","volume":"7","author":"Chiang","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.gendis.2023.03.016_bib37","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1080\/15476286.2020.1850628","article-title":"Differential roles of YTHDF1 and YTHDF3 in embryonic stem cell-derived cardiomyocyte differentiation","volume":"18","author":"Wang","year":"2021","journal-title":"RNA Biol"},{"key":"10.1016\/j.gendis.2023.03.016_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-021-01124-z","article-title":"YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-\u03baB and promote the malignant progression of glioma","volume":"14","author":"Chai","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.gendis.2023.03.016_bib39","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.cell.2020.05.012","article-title":"A unified model for the function of YTHDF proteins in regulating m6A-modified mRNA","volume":"181","author":"Zaccara","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.gendis.2023.03.016_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11899-021-00656-y","article-title":"Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions","volume":"16","author":"Schoenbeck","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.gendis.2023.03.016_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","article-title":"A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.gendis.2023.03.016_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-022-01510-2","article-title":"m6A modification: recent advances, anticancer targeted drug discovery and beyond","volume":"21","author":"Deng","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.gendis.2023.03.016_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-021-01150-x","article-title":"Intracellular delivery of anti-BCR\/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.gendis.2023.03.016_bib44","doi-asserted-by":"crossref","first-page":"116182","DOI":"10.1016\/j.bone.2021.116182","article-title":"Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m6A modification","volume":"154","author":"He","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.gendis.2023.03.016_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12964-016-0129-y","article-title":"Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells","volume":"14","author":"Halbach","year":"2016","journal-title":"Cell Commun Signal"},{"issue":"6","key":"10.1016\/j.gendis.2023.03.016_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.clml.2021.11.012","article-title":"The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the donation program","volume":"22","author":"Sacha","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.gendis.2023.03.016_bib47","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"6","key":"10.1016\/j.gendis.2023.03.016_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004414","article-title":"ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance","volume":"10","author":"Wang","year":"2014","journal-title":"PLoS Genet"},{"issue":"5","key":"10.1016\/j.gendis.2023.03.016_bib49","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.21873\/invivo.12549","article-title":"Combined therapy of ATRA and imatinib mesylate decreases BCR-ABL and ABCB1\/MDR1 expression through cellular differentiation in a chronic myeloid leukemia model","volume":"35","author":"Pinto","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.gendis.2023.03.016_bib50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.gendis.2023.03.016_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/OTT.S278092","article-title":"PARP inhibitor applicability: detailed assays for homologous recombination repair pathway components","volume":"15","author":"O\u2019Sullivan Coyne","year":"2022","journal-title":"Onco Targets Ther"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304223001411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304223001411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:37:58Z","timestamp":1762450678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304223001411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2352304223001411"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2023.03.016","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2023.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}